Scot Ebbinghaus
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 53
- CAR-T cell therapy research 37
- Hepatology top 0.5%
- Immunology top 1%
- Immunotherapy and Immune Responses 18
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 7
- Molecular Biology top 2%
- Melanoma and MAPK Pathways 20
- RNA Interference and Gene Delivery 9
- DNA and Nucleic Acid Chemistry 9
- PI3K/AKT/mTOR signaling in cancer 8
- Co-authors
- Laurence H. HurleyAntoni RibasAdil DaudCaroline RobertOmid HamidAnthony M. JoshuaF. Stephen HodiSoonmo Peter Kang
- Cited by
- OncologyHepatologyImmunology
- Journals
- The Lancet (1 paper)Journal of the American Chemical Society (1 paper)Nucleic Acids Research (2 papers)
- Partner nations
- United StatesFranceCanada
In The Last Decade
Scot Ebbinghaus
93 papers receiving 6.6k citations
Hit Papers
Peers
Comparison fields: 5 of 116
- Oncology 4.0k
- Hepatology 1.1k
- Immunology 1.7k
- Cancer Research 661
- Molecular Biology 2.8k
Countries citing papers authored by Scot Ebbinghaus
This map shows the geographic impact of Scot Ebbinghaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scot Ebbinghaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scot Ebbinghaus more than expected).
Fields of papers citing papers by Scot Ebbinghaus
This network shows the impact of papers produced by Scot Ebbinghaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scot Ebbinghaus. The network helps show where Scot Ebbinghaus may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Scot Ebbinghaus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trialbreakdown → | 2019 | 1300 |
| 3 | 2019 | 208 | |
| 4 | 2019 | 8 | |
| 5 | 2018 | 156 | |
| 6 | 2018 | 117 | |
| 7 | 2017 | 336 | |
| 8 | 2017 | 135 | |
| 9 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)breakdown → | 2017 | 898 |
| 10 | 2017 | 16 | |
| 11 | 2016 | 21 | |
| 12 | 2015 | 173 | |
| 13 | 2014 | 48 | |
| 14 | 2013 | 20 | |
| 15 | 2012 | 1 | |
| 16 | 2005 | 7 | |
| 17 | 2005 | 31 | |
| 18 | 2005 | 241 | |
| 19 | 2004 | 7 | |
| 20 | 1995 | 16 |
About Scot Ebbinghaus
Scot Ebbinghaus is a scholar working on Oncology, Immunology and Cancer Research, having authored 97 papers that have together received 6.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (53 papers), CAR-T cell therapy research (37 papers), Melanoma and MAPK Pathways (20 papers), Immunotherapy and Immune Responses (18 papers), RNA Interference and Gene Delivery (9 papers), DNA and Nucleic Acid Chemistry (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and Cancer Genomics and Diagnostics (7 papers). The work is most often cited by research in Oncology (4.0k citations), Hepatology (1.1k citations) and Immunology (1.7k citations). Scot Ebbinghaus has collaborated with scholars based in United States, France and Canada. Frequent co-authors include Laurence H. Hurley, Antoni Ribas, Adil Daud, Caroline Robert, Omid Hamid, Anthony M. Joshua, F. Stephen Hodi, Soonmo Peter Kang, Jennifer J. Knox and Stephen L. Chan. Their work appears in journals such as The Lancet, Journal of the American Chemical Society and Nucleic Acids Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.